WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company's product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual M ...

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual ...

Core Insights - Aquestive Therapeutics is approaching a significant milestone with the anticipated topline data readout for their Anaphylm (AQST-109) epinephrine sublingual film, expected in Q1 of this year, with a potential New Drug Application (NDA) filing in 2024 [3][11] - The company announced positive Phase III data in March, showing that Anaphylm matches leading auto-injectors in key endpoints, including a quicker time to maximum concentration (Tmax) [3][7] - Following a $75 million public offering, the stock price has decreased from over $6 to approximately $4 per share, despite the positive Phase III results [3][5] Company Background - Aquestive Therapeutics is a pharmaceutical company focused on developing differentiated products using its proprietary PharmFilm platform, which allows for rapid dissolution of oral film drugs [4][5] - The company has a portfolio of five FDA-approved products and over 150 patents worldwide, with a focus on addressing unmet needs in CNS disorders and anaphylaxis [5][6] Financial Performance - In 2023, Aquestive's total revenues increased from $40 million in 2022 to $50.6 million, representing a 26% rise, while the net loss decreased from $54.4 million in 2022 to $7.9 million in 2023 [5][6] - The company ended 2023 with $23.9 million in cash and projects revenues between $48 million to $51 million for 2024 [6][5] Phase III Results - The Phase III study of Anaphylm met primary and secondary endpoints, demonstrating comparability with leading auto-injectors and a faster Tmax, confirming its potential as a needle-free alternative [7][9] - Anaphylm's exposure levels (AUC) were similar to auto-injectors for up to 30 minutes post-dosing, indicating a sustained therapeutic effect [7][9] Upcoming Catalysts - Upcoming catalysts include a self-administration study and an allergen PK study in Q2, a Pediatric PK study in Q3, and pre-NDA discussions in H2 of this year, all leading up to the NDA submission [11][12] - The NDA submission is expected to be a significant catalyst, marking the start of the FDA review timeline [12][11] Market Potential - Anaphylm has the potential to disrupt the epinephrine auto-injector market, which is projected to exceed $1 billion in peak sales, while Aquestive's market cap is around $370 million [12][13] - Revenue estimates suggest strong double-digit growth for Aquestive, with projections nearing half a billion in revenue over the next decade [12][13]

Aquestive Therapeutics (AQST) ended the recent trading session at $4.14, demonstrating a +0.24% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.72%. Elsewhere, the Dow saw a downswing of 1%, while the tech-heavy Nasdaq depreciated by 0.95%.Prior to today's trading, shares of the specialty pharmaceutical company had lost 1.2% over the past month. This has lagged the Medical sector's loss of 0.03% and the S&P 500's gain of 2.16% in that time.The inv ...

Company Performance - Aquestive Therapeutics (AQST) closed at $4.38, showing no change from the previous session, outperforming the S&P 500 which lost 0.14% [1] - The stock has increased by 66.54% over the past month, leading the Medical sector's gain of 0.88% and the S&P 500's gain of 5.34% [1] - The upcoming earnings disclosure is anticipated, with an expected EPS of -$0.09, reflecting a 181.82% decline year-over-year, while revenue is projected at $12.47 million, a 12% increase from the previous year [1] Earnings Estimates - Full-year Zacks Consensus Estimates predict earnings of -$0.38 per share and revenue of $50.85 million, indicating year-over-year changes of -192.31% for earnings and +0.52% for revenue [2] - Recent changes in analyst estimates are crucial as they reflect short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [2] Zacks Rank and Industry Position - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), shows that AQST currently holds a Zacks Rank of 3 (Hold) [3] - The Medical - Drugs industry, to which AQST belongs, has a Zacks Industry Rank of 145, placing it in the bottom 43% of over 250 industries [3] - The Zacks Industry Rank measures the strength of industry groups, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [3]

Aquestive Therapeutics (NASDAQ:AQST) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering for its shares.Aquestive Therapeutics is selling 16,666,667 shares of AQST stock for $4.50 each in this public offering. There’s also a 30-day option for underwriters to acquire an additional 2.5 million shares at that same price.Aquestive Therapeutics is expecting $75 million in gross proceeds from the stock offering. The company will use these funds to continue the deve ...

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting disc ...

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of ...

Aquestive Therapeutics, Inc. (AQST) shares jumped 16% on Mar 15 after the company achieved the primary and secondary endpoints in the two-part phase III pivotal pharmacokinetic clinical study of Anaphylm (epinephrine) Sublingual Film to treat severe allergic reactions. The stock price surge was also likely boosted by findings from the FDA Type C meeting.AQST’s Anaphylm is a non-invasive oral epinephrine product candidate. It has the potential to offer greater convenience of use compared with autoinjectors, ...

Aquestive Therapeutics (AQST) shares ended the last trading session 16% higher at $6.09. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 93% gain over the past four weeks.The sudden surge in the stock price can be attributed to Aquestive's announcement regarding achieving the primary and secondary endpoints in the two-part phase III pivotal pharmacokinetic clinical study of Anaphylm (epinephrine) Sublingual Film to ...